---
title: "Palazestrant (OP-1250) in Previously treated ER-positive HER2-negative advanced or metastatic breast cancer: Humanistic burden and health-related quality of life"
description: "Formulary evidence on Palazestrant (OP-1250) in Previously treated ER-positive HER2-negative advanced or metastatic breast cancer: Humanistic burden and health-related quality of life. Topics: Patient-reported symptoms, side effects, and quality of life in 321 participants with HR+/HER2- metastatic breast cancer in Europe and the United States; Global health status and quality of life in 1250 participants receiving palbociclib plus endocrine therapy in the POLARIS real-world cohort; Pain and EQ-5D-3L utility by metastatic site and pain severity in 739 participants in the United States and Europe; Health-state utilities for stable, responding, and progressive disease: standard gamble study of 100 members of the UK general public; 9 further topics. 13 evidence topics quoted from 13 sources."
canonical: "https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/product-information-and-disease-description/humanistic-burden-and-health-related-quality-of-life"
published: "2026-11-15T20:23:25-05:00"
modified: "2026-11-17T19:46:25-05:00"
---

# Palazestrant (OP-1250) in Previously treated ER-positive HER2-negative advanced or metastatic breast cancer: Humanistic burden and health-related quality of life

<a id="heading-2.2.1.8.1"></a>

## 2.2.1.8.1 Humanistic Burden and Health-related Quality of Life

<a id="topic-2.2.1.8.1-1"></a>

### Patient-reported symptoms, side effects, and quality of life in 321 participants with HR+/HER2- metastatic breast cancer in Europe and the United States

> “Data were derived from the Adelphi Real World Advanced Breast Cancer Disease Specific Programme (DSP)™, a cross-sectional survey of physicians and their patients with HR+/HER2- mBC receiving treatment, conducted in Europe and the United States between August 2022 and February 2023.”
> “Overall, 298 physicians provided data on 1,642 patients, of which 321 patients self-reported data. Tiredness (85.6%), general worry (75.9%), and worry about future health (75.9%) were the most common patient-reported symptoms and side effects overall. Physicians reported bone pain (30.3%) and appetite changes (13.2%) as the most frequent patient symptoms, while estimating that most patients experienced no side effects (55.1%).”
> “Patients with HR+/HER2- mBC experience substantial disease and treatment-mediated side effects, with low patient-physician concordance associated with worse HRQoL.”

Source: [Nsubayi et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13748321/)

<a id="topic-2.2.1.8.1-2"></a>

### Global health status and quality of life in 1250 participants receiving palbociclib plus endocrine therapy in the POLARIS real-world cohort

> “Patients received palbociclib plus endocrine therapy as first-line, second-line or later line of therapy.”
> “Between January 2017 and January 2023, 1250 patients were enrolled and received ≥ 1 palbociclib dose.”
> “For Question 29 (GHS), the proportion of patients with a favorable response significantly increased by ∼13% to 69.3% by month 6, which was maintained at month 12 (68.6%) and month 18 (70.0%). For Question 30 (QoL), the proportion of patients with a favorable response significantly increased by ∼9% to 74.5% by month 6, which was maintained at month 12 (75.0%) and month 18 (73.4%).”

Source: [Rocque et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12596709/)

<a id="topic-2.2.1.8.1-3"></a>

### Pain and EQ-5D-3L utility by metastatic site and pain severity in 739 participants in the United States and Europe

> “Overall, 173 oncologists and 739 patients participated.”
> “The mean (SD) health utility index was 0.73 (0.29) for the total population while the mean (SD) self-reported general health status was 62.0 (20.7)”
> “There was a significant difference in the mean health utility index related to metastatic sites, with mean (SD) index for patients with visceral and bone, bone only and visceral only metastases reported as 0.62 (0.33), 0.68 (0.34) and 0.78 (0.26), respectively”
> “Patients on chemotherapy reported significantly higher proportions of moderate/extreme levels of anxiety/depression (66.7%) and significantly lower general health status (60.7) compared with those on endocrine therapy (53.1% and 64.4, respectively).”

Source: [Wood et al. (2017)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5703387/)

| Worst pain severity | Mean (SD) health utility index |
| --- | --- |
| Mild (1-4) | “0.81 (0.21)” |
| Moderate (5-6) | “0.63 (0.27)” |
| Severe (7-10) | “0.40 (0.45)” |

Source: [Wood et al. (2017)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5703387/)

<a id="topic-2.2.1.8.1-4"></a>

### Health-state utilities for stable, responding, and progressive disease: standard gamble study of 100 members of the UK general public

> “One hundred members of the general public rated them using standard gamble to determine health state utility.”
> “Stable disease on treatment had a utility value of 0.72, with a corresponding gain of +0.07 following a treatment response and a decline by 0.27 for disease progression. Toxicities lead to declines in utility between 0.10 (diarrhoea/vomiting) and 0.15 (febrile neutropenia).”
> “The base state (stable disease with no side effects) had a utility value of 0.715. Moving to responding disease from stable on treatment produced a significant utility gain (+0.075). Moving from stable disease to progressive disease led to a significant decrement in utility (−0.272).”

Source: [Lloyd et al. (2006)](https://pmc.ncbi.nlm.nih.gov/articles/PMC2360509/)

<a id="topic-2.2.1.8.1-5"></a>

### Structured review of health utility elicitation in advanced or metastatic breast cancer

> “A total of 768 publications were identified in the searches, and 26 publications, comprising 18 journal articles and eight submissions to HTA bodies, were included in the evidence review.”
> “the TTO-derived utilities for nine breast cancer health states were collected from two different cohorts, one in the Netherlands and one in Sweden. Of these, the Swedish sample rated progressive and stable disease health states (0.61 and 0.81, respectively) higher than the Dutch sample (0.49 and 0.69, respectively).”
> “Most submissions to HTA bodies obtained utility values from the literature rather than exploring the HRQOL data obtained during clinical development.”

Source: [Hao et al. (2016)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4922814/)

<a id="topic-2.2.1.8.1-6"></a>

### Symptom burden, activity impairment, and work productivity in 152 participants in the US VIRGO observational cohort

> “This cross-sectional analysis evaluated baseline patient-reported outcomes (PROs) in patients with locally recurrent or metastatic breast cancer (MBC) receiving first-line hormonal therapy or chemotherapy and/or targeted therapy in the VIRGO observational study.”
> “Overall, 152 patients (chemotherapy cohort, 104; hormonal therapy cohort, 48) answered questionnaires. Fatigue, decreased sexual interest, disturbed sleep, emotional distress, and drowsiness were the most common severe symptoms, and were of moderate-to-severe intensity in 38.8%-52.0% of patients. Mean percent daily activity impairment was 30% for study patients, and WP impairment ranged from 20% to 40% across indices in employed patients (n, 58).”

Source: [Cleeland et al. (2014)](https://pubmed.ncbi.nlm.nih.gov/25193423/)

<a id="topic-2.2.1.8.1-7"></a>

### Time spent receiving health care during the first 3 months of treatment for metastatic breast cancer

> “Average total time spent on health care ranged from 7% to 10% of all days included within the initial 3 months of treatment, depending on treatment. The greatest time contributions were time spent traveling for care and on inpatient services.”
> “Patients receiving infusion/injection treatments, compared with those receiving oral therapy, spent more time in ambulatory care. Health care time was higher for patients receiving chemotherapeutic agents compared to those receiving hormonal agents.”

Source: [Rocque et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7666754/)

<a id="topic-2.2.1.8.1-8"></a>

### Patient perspectives on progression-free survival and quality of life

> “Virtual roundtables in Europe and the United States and interviews in Japan with breast cancer patients, patient advocates, and thought leaders.”
> “Lengthened OS combined with no worsening or improvement in QoL remain the most important endpoints for mBC patients. Time when the disease is not progressing is meaningful to patients when coupled with improvements in QoL and no added treatment toxicity.”

Source: [Mertz et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9307669/)

<a id="topic-2.2.1.8.1-9"></a>

### Patient-reported outcomes in EMBER-3: imlunestrant, imlunestrant plus abemaciclib, and fulvestrant or exemestane

> “Most (72.3%) fulvestrant-treated patients reported injection site reactions at any time. Diarrhea frequency was consistently higher in the combination arm of imlunestrant–abemaciclib.”
> “GHS/QoL and function were maintained across treatment arms, despite a higher incidence of diarrhea in the imlunestrant–abemaciclib group.”

Source: [Curigliano et al. (2026b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13091516/)

<a id="topic-2.2.1.8.1-10"></a>

### Patient-reported outcomes in CAPItello-291: capivasertib plus fulvestrant versus placebo plus fulvestrant

> “Median time to deterioration in EORTC QLQ-C30 GHS/QOL was 24·9 months (95% CI 13·8 to not reached) in the capivasertib-fulvestrant group and 12·0 months (10·2 to 15·7) in the placebo-fulvestrant group (hazard ratio [HR] 0·70, 95% CI 0·53 to 0·92).”
> “Time to deterioration HRs for all EORTC QLQ-C30 and QLQ-BR23 subscale scores showed little difference between the treatment groups, except for diarrhoea, which was worse in the capivasertib-fulvestrant group than in the placebo-fulvestrant group (HR 2·75, 95% CI 2·01-3·81).”

Source: [Oliveira et al. (2024a)](https://pubmed.ncbi.nlm.nih.gov/39214106/)

<a id="topic-2.2.1.8.1-11"></a>

### Patient-reported outcomes in SOLAR-1: alpelisib plus fulvestrant versus placebo plus fulvestrant

> “Time to 10% deterioration for Global Health Status/QoL was similar between arms (hazard ratio, 1.03; 95% CI, 0.72 to 1.48). Compared with placebo, deterioration in social functioning and in diarrhea, appetite loss, nausea or vomiting, and fatigue symptom subscales occurred with alpelisib.”

Source: [Ciruelos et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8210974/)

<a id="topic-2.2.1.8.1-12"></a>

### Patient-reported outcomes in SERENA-6: switch to camizestrant at ESR1 mutation emergence during first-line therapy

> “Switching to camizestrant-CDK4/6i delayed TTD and reduced the risk of deterioration in patient-reported cancer symptoms [pain (hazard ratio 0.57, 95% confidence interval 0.37-0.86), fatigue (0.75, 0.46-1.24), shortness of breath/dyspnoea (0.52, 0.28-0.93), breast symptoms (0.59, 0.28-1.24) and arm symptoms (0.69, 0.34-1.39)] and functioning [physical (0.74, 0.44-1.24), role (0.73, 0.48-1.10) and emotional (0.51, 0.29-0.87)] compared with AI-CDK4/6i.”

Source: [Mayer et al. (2026a)](https://pubmed.ncbi.nlm.nih.gov/41125211/)

<a id="topic-2.2.1.8.1-13"></a>

### Health-related quality of life with first-line versus second-line CDK4/6 inhibitor use in SONIA

> “HRQOL was assessed using the Functional Assessment of Cancer Therapy-Breast (FACT-B) and EuroQoL 5-dimensions 5-level questionnaires at up to 11 time points over the course of both treatment lines (follow-up) until SONIA treatment discontinuation.”
> “No clinically or statistically significant differences in HRQOL were observed between treatment arms during follow-up. The estimated mean difference in FACT-B total score (CDK4/6i in second-line as reference) was -0.66 (95% confidence interval [CI] = -2.14 to 0.82; P = .39).”

Source: [Wortelboer et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/41270788/)

## Related pages
- [Palazestrant (OP-1250): Previously treated ER-positive HER2-negative advanced or metastatic breast cancer](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer) · [Markdown](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer.md)
- [Palazestrant (OP-1250) in Previously treated ER-positive HER2-negative advanced or metastatic breast cancer: Terms and abbreviations](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/terms-and-abbreviations.md)
- [Palazestrant (OP-1250): Previously treated ER-positive HER2-negative advanced or metastatic breast cancer](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/executive-summary) · [Markdown](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/executive-summary.md)
- [Palazestrant (OP-1250) in Previously treated ER-positive HER2-negative advanced or metastatic breast cancer: Product information and disease description](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/product-information-and-disease-description.md)
- [Palazestrant (OP-1250) in Previously treated ER-positive HER2-negative advanced or metastatic breast cancer: Clinical evidence](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/clinical-evidence.md)
- [Palazestrant (OP-1250) in Previously treated ER-positive HER2-negative advanced or metastatic breast cancer: Economic information and modeling report](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/economics) · [Markdown](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/economics.md)
- [Palazestrant (OP-1250) in Previously treated ER-positive HER2-negative advanced or metastatic breast cancer: References](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/references) · [Markdown](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/references.md)
